Sullivan Christopher Ryan: insider trades.
Sullivan Christopher Ryan reported 10 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($1.8M), across 1 company.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 5
- Companies
- 1
- Name as filed
- Sullivan Christopher Ryan
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | Officer · Chief Financial Officer | 10 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-16 | Avalo Therapeutics, Inc. | M | 12,394 | $9.88 | 52,294 | Form 4 |
| 2026-09-16 | Avalo Therapeutics, Inc. | S | 12,394 | $16.33 | 39,900 | Form 4 |
| 2026-09-10 | Avalo Therapeutics, Inc. | M | 10,185 | $8.04 | 50,085 | Form 4 |
| 2026-09-10 | Avalo Therapeutics, Inc. | S | 10,185 | $17.62 | 39,900 | Form 4 |
| 2026-08-18 | Avalo Therapeutics, Inc. | S | 31,031 | $20.05 | 39,900 | Form 4 |
| 2026-08-18 | Avalo Therapeutics, Inc. | M | 31,031 | $9.88 | 70,931 | Form 4 |
| 2026-08-17 | Avalo Therapeutics, Inc. | S | 3,749 | $19.94 | 39,900 | Form 4 |
| 2026-08-17 | Avalo Therapeutics, Inc. | S | 37,945 | $19.85 | 43,649 | Form 4 |
| 2026-08-17 | Avalo Therapeutics, Inc. | M | 2,876 | $9.88 | 81,594 | Form 4 |
| 2026-08-17 | Avalo Therapeutics, Inc. | M | 37,945 | $9.88 | 78,718 | Form 4 |
Questions
What stock did Sullivan Christopher Ryan buy or sell?
Sullivan Christopher Ryan reported 10 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($1.8M), across 1 company.
Is Sullivan Christopher Ryan the same person as other filers with this name?
This page covers SEC CIK 1810417 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/sullivan-christopher-ryan-1810417.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.